Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 667-672

  Maitland, D ^a   Jackson, A ^a   Osorio, J ^a   Mandalia, S ^a   Gazzard, B G ^a   Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Abacavir; Adherence; HIV; Lamivudine; Oncedaily; Treatment satisfaction

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RITONAVIR; TENOFOVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 52649154648     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00618.x     Document Type: Article

References (27)

1. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135: 17-26.
2. Moore DM, Hogg RS, Yip B et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40: 288-293.
3. Gao X, Nau DP, Rosenbluth SA et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000; 12: 387-398.
4. Miller LG, Liu H, Hays RD et al. Knowledge of antiretroviral regimen dosing and adherence: A longitudinal study. Clin Infect Dis 2003; 36: 514-518.
5. Gordillo V, del Amo J, Soriano V et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-1769.
6. Kleeberger CA, Phair JP, Strathdee SA et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26: 82-92.
7. Ammassari A, Murri R, Pezzotti P et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-449.
8. Stone VE, Jordan J, Tolson J et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808-816.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
10. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) Study. Int J STD AIDS 2003; 14 (Suppl. 1): 34-36.
11. Moyle G, DeJesus E, Cahn P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38: 417-425.
12. GlaxoSmithKline. Kivexa Package Insert. Research Triangle Park, NC: GlaxoSmithKline, 2004.
13. Liu H, Golin CE, Miller LG et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 136: 968-977.
14. Arnsten JH, Demas PA, Farzadegan H et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug abusers: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-1423.
15. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: Adherence assessment or intervention? HIV Clin Trials 2002; 3: 45-51.
16. Portsmouth S, Osorio J, McCormick K et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: A 24-week randomized trial of treatment simplification using prolonged-release capsules. HIV Med 2005; 6: 185-190.
17. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-733.
18. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503.
19. Moore KH, Barrett JE, Shaw S et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999; 13: 2239-2250.
20. Piliero P, Shachoy-Clark AD, Para M et al. A study examining the pharmacokinetics of abacavir and intracellular carbovir triphosphate (GSK Protocol CNA10905). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract A-1797].
21. Lamarca A, Clumeck N, Plettenberg A et al. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr 2006; 41: 598-606.
22. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.
23. Garcia de Olalla P, Knobel H, Carmona A et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105-110.
24. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45: 4-8.
25. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007; 8: 19-23.
26. Boffito M, Else L, Back D et al. Pharmacokinetics of atazanavir/ ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 hours following drug intake cessation. AIDS, in press.
27. Molina JM, Podsadecki TJ, Johnson MA et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23: 1505-1514.